Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • IN BRIEF

Targeting TREM2 to enhance immunotherapy

  1. Sarah Crunkhorn
    View author publications

    You can also search for this author in PubMed  Google Scholar

Immune checkpoint blockade is ineffective in some tumours, in part owing to the presence of immunosuppressive myeloid cells in the microenvironment. Here, Molgora et al. report that deficiency of the myeloid receptor TREM2 or treatment with an anti-TREM2 mAb reduces tumour growth in mouse cancer models and enhances the efficacy of anti-PD1 immunotherapy, while triggering changes in the tumour-infiltrating macrophage populations. TREM2 was expressed in infiltrating macrophages in more than 200 human tumours, and expression correlated with worse survival in colorectal and breast cancer.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 672 (2020)

doi: https://doi.org/10.1038/d41573-020-00152-7

References

  1. Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900 (2020)

    Article  PubMed  Google Scholar 

Download references

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links